Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RENB-HV01
- Development stage
- Discontinued
- Lead developer
- Renovaro
- Modality
- Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
RENB-HV01 is an investigational autologous cell therapy developed for the potential curative treatment of HIV. The approach involves gene-editing autologous human hematopoietic stem cells (HSCs) to knock down C-C chemokine receptor type 5 (CCR5) expression, a key co-receptor required for HIV entry into immune cells. The modified HSCs are then transplanted back into the patient, with the goal of achieving durable engraftment and long-term control or eradication of HIV without ongoing antiretroviral therapy (ART). Renovaro Biosciences developed a novel aldehyde dehydrogenase (ALDH) gene modification technology to enhance engraftment efficiency of these CCR5-modified HSCs. Although preclinical results have been promising, further development was considered costly and long-term; as such, Renovaro Biosciences sub-licensed this technology to Caring Cross for continued development[1][2][3].
- Brand names
- RENB-HV-01RENB-HV01RENB-HV 01
- Other names
- RENB-HV-01RENB-HV01RENB-HV 01
02
Targets
CCR5 (C-C chemokine receptor type 5)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on RENB-HV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RENB-HV01.